TruTechnologies chairman and co-founder argues that while Operation TrialBlazer is directionally correct in targeting regulatory friction, it misses the larger problem.
Dr. Richard Graham
Advertisement
Dr. Richard Graham is chairman of the board at Tru Technologies.
Articles by Dr. Richard Graham
TruTechnologies’ Dr. Richard Graham explains where he sees the actual issues that need to be addressed at FDA.
Dr. Richard Graham, chairman and co-founder of TruTechnologies, discusses the importance of global clinical trials while also being a center for these trials.
TruTechnologies’ chairman and co-founder Dr. Richard Graham explains why Australia and China are the main competitors for clinical trials.
Dr. Richard Graham from TruTechnologies details the likelihood that Project Trialblazer reduces trial times by 6-to-12 months.
Dr. Richard Graham discusses the distinction between real-time data and real-time oversite and how one option may present better results than the other.
Dr. Richard Graham details how real-time data review may reduce timelines but also allow for bad data or outcomes.
Dr. Richard Graham explains how FDA’s new program allows for the usage of real-time data during clinical trials.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
The Significance of FDA’s First Warning Letter for Inappropriate Use of AI
2
Jazz Pharmaceuticals to Acquire Actio Biosciences for $1.32 Billion
3
Generating Commercial Evidence from Agentic Field and Brand Engagement to Accelerate Launch Performance
4
M&A Roundup: Novo Nordisk Enters AI Drug Discovery Partnership with Amazon, Innate Pharma Partners with Sobi, Innovent Enters Commercialization Agreement with Daiichi Sankyo
5